, Volume 15, Supplement 1, pp 61–67

Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor

  • Federica Guaraldi
  • Valentina Corazzini
  • Gary L. Gallia
  • Silvia Grottoli
  • Karen Stals
  • Nadezhda Dalantaeva
  • Lawrence A. Frohman
  • Márta Korbonits
  • Roberto Salvatori


Familial isolated pituitary adenoma (FIPA), defined as the occurrence of at least two cases of pituitary adenoma in a family that does not exhibit features of syndromic diseases, such as Carney complex or Multiple Endocrine Neoplasia type 1 or 4, is a rare autosomal dominant disease with low penetrance. About 20 % of the families with FIPA harbor inactivating mutation in aryl hydrocarbon receptor-interacting protein gene (AIP) associated with loss of heterozygosity of the same genetic locus (11q13) in the tumor. Rarely different types of extra-pituitary tumors have been described in the setting of AIP mutation-positive FIPA. We present the case of a patient who was diagnosed with acromegaly due to the AIP mutation c.241C>T (p.R81X) at the age of 34 years, and treated by transsphenoidal surgery. At the age of 43 years she was diagnosed with a meningioma, and at age 46 had recurrence of the somatotropinoma. Genetic studies demonstrated loss of the normal allele (by sequencing and microsatellite analysis) in DNA from the pituitary adenoma but not from the meningioma, suggesting a selective involvement of AIP mutation in the pathogenesis of the pituitary adenoma, and a casual association with the meningioma. Further investigations are required to define the exact role of AIP in non-pituitary tumorigenesis.


Acromegaly Meningioma Familial isolated pituitary adenoma 


  1. 1.
    Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189–3202PubMedCrossRefGoogle Scholar
  2. 2.
    Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M (2010) Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab 21:419–427PubMedCrossRefGoogle Scholar
  3. 3.
    Guaraldi F, Salvatori R (2011) Familial isolated pituitary adenomas: from genetics to therapy. Clin Transl Sci 4:55–62PubMedCrossRefGoogle Scholar
  4. 4.
    Soares BS, Frohman LA (2002) Isolated familial somatotropinoma. Pituitary 7:95–101CrossRefGoogle Scholar
  5. 5.
    Benlian P, Giraud S, Lahlou N, Roger M, Blin C, Holler C, Lenoir G, Sallandre J, Calender A, Turpin G (1995) Familial acromegaly: a specific clinical entity- further evidence from the genetic study of a three-generation family. Eur J Endocrinol 133:451–456PubMedCrossRefGoogle Scholar
  6. 6.
    Yamada S, Yoshimoto K, Sano T, Takada K, Itakura M, Usui M, Teramoto A (1997) Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 82:239–242PubMedCrossRefGoogle Scholar
  7. 7.
    Gadelha MR, Prezant TR, Une KN, Glick RP, Moskal SF II, Vaisman M, Melmed S, Kineman RD, Frohman LA (1999) Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab 84:249–256PubMedCrossRefGoogle Scholar
  8. 8.
    Gadelha MR, Une KN, Rohde K, Vaisman M, Kineman RD, Frohman LA (2000) Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. J Clin Endocrinol Metab 85:707–714PubMedCrossRefGoogle Scholar
  9. 9.
    Luccio-Camelo DC, Une KN, Ferreira RE, Nickolov R, Bronstein MD, Vaisman M, Teh BT, Frohman LA, Mendonça BB, Gadelha MR (2004) A meiotic recombination in a new isolated familial somatotropinoma kindred. Eur J Endocrinol 150:643–648PubMedCrossRefGoogle Scholar
  10. 10.
    Soares BS, Eguchi K, Frohman LA (2005) Tumor deletion mapping on chromosome 11q13 in eight families with isolated familial somatotropinoma and in 15 sporadic somatotropinomas. J Clin Endocrinol Metab 90:6580–6587PubMedCrossRefGoogle Scholar
  11. 11.
    Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montañana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabaté MI, Villa C, Popelier M, Salvatori R, Jennings J, Longás AF, Labarta Aizpún JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellinghen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an International Collaborative Study. J Clin Endocrinol Metab 95:E373–E383Google Scholar
  12. 12.
    Gadelha MR, Kineman RD, Frohman LA (1999) Familial somatotropinomas: clinical and genetic aspects. Endocrinologist 9:277–285CrossRefGoogle Scholar
  13. 13.
    Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M (2008) The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93:2390–2401PubMedCrossRefGoogle Scholar
  14. 14.
    Renehan AG, Brennan BM (2002) Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab 22:639–657CrossRefGoogle Scholar
  15. 15.
    Clayton PE, Banerjee I, Murray PG, Renehan AG (2007) Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 7:11–24CrossRefGoogle Scholar
  16. 16.
    Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, Olsen JH, Baron JA, Fraumeni JF Jr (2002) Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13:395–400PubMedCrossRefGoogle Scholar
  17. 17.
    Kauppinen-Makelin R, Sane T, Valimaki MJ, Markkanen H, Niskanen L, Ebeling T, Jaatinen P, Juonala M (2010) Finnish Acromegaly Study Group, Pukkala, E’: increased cancer incidence in acromegaly—a nationwide survey. Clin Endocrinol 72:278–279CrossRefGoogle Scholar
  18. 18.
    Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730–2734PubMedCrossRefGoogle Scholar
  19. 19.
    Glick RP, Lichtor T, Unterman TG (1997) Insulin-like growth factors in central nervous system tumors. J Neurooncol 35:315–325PubMedCrossRefGoogle Scholar
  20. 20.
    Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244PubMedCrossRefGoogle Scholar
  21. 21.
    CazabaTL Libe R, Perlemoine K, René-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P, Bertherat J, Raffin-Sanson ML (2007) Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 157:1–8CrossRefGoogle Scholar
  22. 22.
    Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Mäkinen MJ, Vierimaa O, Paschke R, Saeger W, van der Luijt RB, Sane T, Robledo M, De Menis E, Weil RJ, Wasik A, Zielinski G, Lucewicz O, Lubinski J, Launonen V, Vahteristo P, Aaltonen LA (2007) Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci USA 104:4101–4105PubMedCrossRefGoogle Scholar
  23. 23.
    Toledo RA, Mendonca BB, Fragoso MC, Soares IC, Almeida MQ, Moraes MB, Lourenço DM Jr, Alves VA, Bronstein MD, Toledo SP (2010) Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis. Clinics (Sao Paulo) 65:407–415CrossRefGoogle Scholar
  24. 24.
    Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, Guasti L, Chapple JP, Trivellin G, Gueorguiev M, Guegan K, Stals K, Khoo B, Kumar AV, Ellard S, Grossman AB, Korbonits M (2010) International FIPA Consortium: characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat 31:950–960PubMedCrossRefGoogle Scholar
  25. 25.
    Tahir A, Chahal HS, Korbonits M (2010) Molecular genetics of the AIP gene in familial pituitary tumorigenesis. Prog Brain Res 182:229–253PubMedCrossRefGoogle Scholar
  26. 26.
    Abs R, Parizel PM, Willems PJ, Van de Kelft E, Verlooy J, Mahler C, Verhelst J, Van Marck E, Martin JJ (1993) The association of meningioma and pituitary adenoma: report of seven cases and review of the literature. Eur Neurol 33:416–422PubMedCrossRefGoogle Scholar
  27. 27.
    Chahal HS, Stals K, Unterlander M, Balding DJ, Thomas MG, Kumar AV, Besser GM, Atkinson AB, Morrison PJ, Howlett TA, Levy MJ, Orme SM, Akker SA, Abel RL, Grossman AB, Burger J, Ellard S, Korbonits M (2011) AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med 364:43–50PubMedCrossRefGoogle Scholar
  28. 28.
    Gullu BE, Celik O, Gazioglu N, Kadioglu P (2010) Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 13:242–248PubMedCrossRefGoogle Scholar
  29. 29.
    Correa LL, Lima GA, Paiva HB, Silva CM, Cavallieri SA, Miranda LC, Gadelha MR (2009) Prostate cancer and acromegaly. Arq Bras Endocrinol Metabol 53:963–968PubMedCrossRefGoogle Scholar
  30. 30.
    Bunick EM, Mills LC, Rose LI (1978) Association of acromegaly and meningiomas. JAMA 240:1267–1268PubMedCrossRefGoogle Scholar
  31. 31.
    Cannavo S, Curto L, Fazio R, Paterniti S, Blandino A, Marafioti T, Trimarchi F (1993) Coexistence of growth hormone-secreting pituitary adenoma and intracranial meningioma: a case report and review of the literature. J Endocrinol Invest 16:703–708PubMedGoogle Scholar
  32. 32.
    Curto L, Squadrito S, Almoto B, Longo M, Granata F, Salpietro F, Torre ML, Marini F, Trimarchi F, Cannavo S (2007) MRI finding of simultaneous coexistence of growth hormone-secreting pituitary adenoma with intracranial meningioma and carotid artery aneurysms: report of a case. Pituitary 10:299–305PubMedCrossRefGoogle Scholar
  33. 33.
    De Menis E, Tulipano G, Villa S, Billeci D, Bonfanti C, Pollara P, Pauletto P, Giustina A (2003) Development of a meningioma in a patient with acromegaly during octreotide treatment: are there any causal relationship? J Endocrinol Invest 26:359–363PubMedGoogle Scholar
  34. 34.
    Drake WM, Grossman AB, Hutson RK (2005) Effect of treatment with pegvisomant on meningioma growth in vivo. Eur J Endocrinol 152:161–162PubMedCrossRefGoogle Scholar
  35. 35.
    Fernandez A, Karavitaki N, Ansorge O, Fazal-Sanderson V, Wass JA (2008) Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? Pituitary. 11:325–330PubMedCrossRefGoogle Scholar
  36. 36.
    Furtado SV, Venkatesh PK, Ghosal N, Hegde AS (2010) Coexisting intracranial tumors with pituitary adenomas: genetic association or coincidence? J Cancer Res Ther 6:221–223PubMedCrossRefGoogle Scholar
  37. 37.
    Gori G, Nucci U (1965) Association of frontal ependymoma and hypophyseal adenoma. Minerva Neurochir 9:211–213PubMedGoogle Scholar
  38. 38.
    Gorman P, Hewer RL (1985) Stroke due to atrial myxoma in a young woman with co-existing acoustic neuroma and pituitary adenoma. J Neurol Neurosurg Psychiatry 48:718–719PubMedCrossRefGoogle Scholar
  39. 39.
    Honegger J, Buchfelder M, Schrell U, Adams EF, Fahlbusch R (1989) The coexistence of pituitary adenomas and meningiomas: three case reports and a review of the literature. Br J Neurosurg 3:59–69PubMedCrossRefGoogle Scholar
  40. 40.
    Irsy G, Goth M, Slovik F, Bálint K, Szabolcs I, Pásztor E, Szilágyi G (1985) Growth hormone producing pituitary adenoma and meningioma. Zentralbl Neurochir 46:337–343PubMedGoogle Scholar
  41. 41.
    Koutourousiou M, Seretis A, Kontogeorgos G (2009) Intra-sellar schwannoma co-existing with GH-secreting pituitary adenoma. Acta Neurochir (Wien) 151:1693–1697CrossRefGoogle Scholar
  42. 42.
    Mathuriya SN, Vasishta RK, Dash RJ, Kak VK (2000) Pituitary adenoma and parasagittal meningioma: an unusual association. Neurol India 48:72–74PubMedGoogle Scholar
  43. 43.
    Yarman S, Minareci O (2004) Value of petrosal sinus sampling: coexisting acromegaly, empty sella and meningioma. Neuroradiology 46:1027–1030PubMedCrossRefGoogle Scholar
  44. 44.
    Lee Y, Liu J, Patel S, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S (2010) Genomic landscape of meningiomas. Brain Pathol 20:751–762PubMedCrossRefGoogle Scholar
  45. 45.
    Collins VP (2004) Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 75(Suppl 2):ii2–ii11PubMedCrossRefGoogle Scholar
  46. 46.
    Friend KE (2001) Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm IGF Res 11(Suppl A):S121–S123PubMedCrossRefGoogle Scholar
  47. 47.
    Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623–646PubMedCrossRefGoogle Scholar
  48. 48.
    Szymas J, Schluens K, Liebert W, Petersen I (2002) Genomic instability in pituitary adenomas. Pituitary 5:211–219PubMedCrossRefGoogle Scholar
  49. 49.
    Trivellin G, Korbonits M (2011) AIP and its interacting partners. J Endocrinol 210:137–155PubMedCrossRefGoogle Scholar
  50. 50.
    Chang YF, Imam JS, Wilkinson MF (2007) The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem 76:51–74PubMedCrossRefGoogle Scholar
  51. 51.
    Ozfirat Z, Korbonits M (2010) AIP gene and familial isolated pituitary adenomas. Mol Cell Endocrinol 326:71–79PubMedCrossRefGoogle Scholar
  52. 52.
    Toledo RA, Lourenco DM Jr, Liberman B, Cunha-Neto MB, Cavalcanti MG, Moyses CB, Toledo SP, Dahia PL (2007) Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. J Clin Endocrinol Metab 92:1934–1937PubMedCrossRefGoogle Scholar
  53. 53.
    Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P, Elenkova A, Tabarin A, Desailloud R, Maiter D, Schürmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves LA, Chabre O, Montañana CF, Hana V, Halaby G, Delemer B, Aizpún JI, Sonnet E, Longás AF, Hagelstein MT, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A (2011) High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 165:509–515PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Federica Guaraldi
    • 1
  • Valentina Corazzini
    • 2
  • Gary L. Gallia
    • 3
  • Silvia Grottoli
    • 1
  • Karen Stals
    • 4
  • Nadezhda Dalantaeva
    • 5
  • Lawrence A. Frohman
    • 6
  • Márta Korbonits
    • 5
  • Roberto Salvatori
    • 2
  1. 1.Division of Endocrinology, Department of Internal MedicineUniversity of TurinTurinItaly
  2. 2.Division of Endocrinology and Metabolism, Department of MedicineJohns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Department of NeurosurgeryJohns Hopkins School of MedicineBaltimoreUSA
  4. 4.Department of Molecular GeneticsRoyal Devon and Exeter Foundation TrustExeterUK
  5. 5.Department of Endocrinology, Barts and the London School of MedicineQueen Mary University of LondonCharterhouse Square, LondonUK
  6. 6.Section of Endocrinology, Diabetes and Metabolism, Department of MedicineUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations